Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study

Pivotal trials showed the effectiveness of the monoclonal antibody ocrelizumab in relapsing and progressive multiple sclerosis (MS). However, data on everyday practice in MS patients and markers of treatment effectiveness are scarce. We aimed to collect real-world data from ocrelizumab-treated MS pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Lanzillo, Roberta, Carotenuto, Antonio, Signoriello, Elisabetta, Iodice, Rosa, Miele, Giuseppina, Bisecco, Alvino, Maniscalco, Giorgia Teresa, Sinisi, Leonardo, Romano, Felice, Di Gregorio, Maria, Lavorgna, Luigi, Trojsi, Francesca, Moccia, Marcello, Fratta, Mario, Capasso, Nicola, Dubbioso, Raffaele, Petracca, Maria, Spiezia, Antonio Luca, Gallo, Antonio, Petruzzo, Martina, De Angelis, Marcello, Bonavita, Simona, Lus, Giacomo, Tedeschi, Gioacchino, Brescia Morra, Vincenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029051/
https://www.ncbi.nlm.nih.gov/pubmed/35456175
http://dx.doi.org/10.3390/jcm11082081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029051/
https://www.ncbi.nlm.nih.gov/pubmed/35456175
http://dx.doi.org/10.3390/jcm11082081

Ejemplares similares